Risk factors for developing osteonecrosis of jaw in advanced cancer patients underwent zoledronic acid treatment
Risk factors for developing osteonecrosis of jaw in advanced cancer patients underwent zoledronic acid treatment
复制标题
唑来膦酸治疗晚期癌症患者发生颌骨骨坏死的危险因素
DOI：
10.2217/fon-2019-0352
复制
发表时间：
2019-10-01
期刊：
影响因子：
3.3
通讯作者：
Chen, Jiayi
中科院分区：
文献类型：
--
作者：
Qi, Wei-Xiang;Zhao, Shengguang;Chen, Jiayi
目的：研究骨转移患者的晚期癌症患者的颌骨（ONJ）的危险因素接受唑来膦酸（ZA）治疗。材料与方法：进行单变量和多元逻辑回归分析，以研究与晚期癌症患者发展的因素。结果：总共包括2214例晚期癌症患者。与ONJ相关的危险因素的单变量和多元逻辑回归分析分析年龄较大（> = 66岁，危险比[HR]：3.21； P = 0.007），贫血（HR：3.29; P = 0.006）和ZA暴露持续时间和ZA暴露持续时间（ZA暴露持续时间（1至2年），HR：3.91，p = 0.00，P = 0.01，p <0.01，p <0.011，> = 2年， 分别。结论：年龄较大，贫血和/或超过1年的ZA治疗患者患ONJ的风险很高。
Aim: To investigate the risk factors for developing osteonecrosis of jaw (ONJ) in advanced cancer patients with bone metastases underwent zoledronic acid (ZA) treatment. Materials & methods: Univariate and multivariate logistic regression analyses were performed to investigate factors associated with developing ONJ in advanced cancer patients. Results: A total of 2214 advanced cancer patients were included. Univariate and multivariate logistic regression analyses for risk factors associated with ONJ were older age (>= 66 years, hazards ratio [HR]: 3.21; p = 0.007), anemia (HR: 3.29; p = 0.006) and duration of ZA exposure (between 1 and 2 years, HR: 3.91, p = 0.01; >= 2 years, HR: 8.07, p < 0.001), respectively. Conclusion: Patients with older age, anemia and/or more than 1 year of ZA treatment are at high risk of developing ONJ.